FealtySign in

Xylem Inc.

(XYL)

CIK 1524472 · SEC filings only

Not gradedDividend record
shown as history
company entity
49 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

49 declarations · 14 raised · 34 held · 0 cut · held 48 quarters

  1. HELD$0.4300/shperiod ended 2026-06-30Filing ↗
  2. RAISED$0.4300/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.4000/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.4000/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.4000/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.3600/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.3600/shperiod ended 2024-06-30Filing ↗
  8. HELD$0.3600/shperiod ended 2024-03-31Filing ↗
  9. RAISED$0.3600/shperiod ended 2023-12-31Filing ↗
  10. HELD$0.3300/shperiod ended 2023-09-30Filing ↗
  11. HELD$0.3300/shperiod ended 2023-06-30Filing ↗
  12. HELD$0.3300/shperiod ended 2023-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
3 resolved promises

Not enough GAAP-comparable guidance to grade

3 of the 4 resolved guidance promises needed to publish a reliability grade. Much of this company’s guidance is non-GAAP, which has no comparable GAAP actual in SEC XBRL to check it against — shown below, never scored. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (30)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Jul 28, 2026
    This results in full-year adjusted earnings per share of $5.55 to $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 28, 2026
    This results in full-year adjusted earnings per share of $5.35 to $5.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 10, 2026
    adjusted earnings per share of $5.35 to $5.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Oct 28, 2025
    This results in full-year adjusted earnings per share of $5.03 to $5.08
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Jul 31, 2025
    This results in full-year adjusted earnings per share of $4.70 to $4.85
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Apr 29, 2025
    This results in full-year adjusted earnings per share of $4.50 to $4.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Feb 4, 2025
    2025 full-year adjusted earnings per share guidance range of $4.50 to $4.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 31, 2024
    This results in adjusted earnings per share of $4.22 to $4.24
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Jul 30, 2024
    This results in adjusted earnings per share of $4.18 to $4.28
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · May 2, 2024
    This results in adjusted earnings per share of $4.10 to $4.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Feb 6, 2024
    adjusted earnings per share range of $4.00 to $4.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Oct 31, 2023
    This results in adjusted earnings per share of $3.71 to $3.73
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Aug 2, 2023
    This results in adjusted earnings per share of $3.50 to $3.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · May 4, 2023
    This results in adjusted earnings per share of $3.15 to $3.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Feb 7, 2023
    This results in adjusted earnings per share of $3.00 to $3.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Nov 1, 2022
    This results in adjusted earnings per share of $2.65 to $2.75
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Aug 2, 2022
    This results in adjusted earnings per share of $2.50 to $2.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. revenue guidance fy · Aug 2, 2022
    Xylem now expects full-year 2022 organic revenue growth to be in the range of 8 to 10 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. revenue guidance fy · May 4, 2022
    Xylem now expects full-year 2022 organic revenue growth to be in the range of 4 to 6 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · May 4, 2022
    This results in adjusted earnings per share of $2.40 to $2.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Feb 3, 2022
    This results in adjusted earnings per share of $2.35 to $2.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. revenue guidance fy · Nov 2, 2021
    Xylem now expects full-year organic revenue growth to be in the range of 3 to 4 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · Nov 2, 2021
    Full-year adjusted earnings per share is now expected to be in the range of $2.40 to $2.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · Aug 3, 2021
    Full-year adjusted earnings per share is now expected to be in the range of $2.55 to $2.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. revenue guidance fy · Aug 3, 2021
    Xylem now expects full-year organic revenue growth to be in the range of 6 to 8 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. revenue guidance fy · Aug 3, 2021
    9 to 11 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. revenue guidance fy · May 4, 2021
    8 to 10 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance fy · May 4, 2021
    Full-year adjusted earnings per share is now expected to be in the range of $2.50 to $2.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. revenue guidance fy · May 4, 2021
    Xylem now expects full year organic revenue growth to be in the range of 5 to 7 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Feb 4, 2021
    This results in adjusted earnings per share of $2.35 to $2.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (7) · 14 superseded

Open · revenue guidance q

expectation that organic revenue will be down in the range of 8 to 12 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance q

down 10 to 14 percent on a reported basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

Xylem expects fourth quarter organic revenue declines in the range of 6 to 8 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Xylem forecasts full-year 2021 revenue in the range of $5.16 to $5.26 billion

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Xylem now expects full-year 2022 organic revenue growth to be in the range of 9 to 10 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

approximately 4 percent on a reported basis

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Xylem now forecasts full-year 2026 revenue of approximately $9.2 billion

resolves in ~198 daysreceipt →
Superseded · revenue guidance fy

Xylem now expects full-year 2023 revenue of approximately $7.2 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2022 revenue in the range of $5.25 to $5.35 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem now expects full-year 2024 revenue of approximately $8.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2025 revenue of approximately $8. 6 to $8. 7 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2024 revenue of approximately $8.4 to $8.5 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem now forecasts full-year 2026 revenue of approximately $9.2 to $9.3 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2025 revenue of approximately $8. 7 to $8. 8 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2023 revenue in the range of $5.70 to $5.80 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem now expects full-year 2024 revenue of $8.55 billion

revised by a later guidance$8.5500receipt →
Superseded · revenue guidance fy

Xylem forecasts full-year 2026 revenue of approximately $9.1 to $9.2 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem now forecasts full-year 2025 revenue of approximately $8. 9 to $9.0 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

and 3 to 5 percent on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

up approximately 15 to 16 percent on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Xylem now expects full-year 2023 revenue growth of 8 to 9 percent on an organic and reported basis.

revised by a later guidancereceipt →

Credibility timeline

WITHDRAWN · Jul 30, 2020BEAT · Feb 28, 2024KEPT · Mar 3, 2025KEPT · Feb 25, 2026
20202026
Timeline as a list
  • Jul 30, 2020WITHDRAWNXylem withdrew 2020 guidance earlier this year
  • Feb 28, 2024BEATXylem now expects full-year 2023 revenue of approximately $7.3 billion
  • Mar 3, 2025KEPTXylem expects full-year 2024 revenue of $8.5 billion
  • Feb 25, 2026KEPTXylem now forecasts full-year 2025 revenue of approximately $9.0 billion
3 resolved guidance promises · 30dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →